Defendant Name: Novartis AG

Defendant Type: Public Company
SIC Code: 2834
CUSIP: 66987V10

Initial Case Details

Legal Case Name In the Matter of Novartis AG
First Document Date 23-Mar-2016
Initial Filing Format Administrative Action
File Number 3-17177
Allegation Type Foreign Corrupt Practices Act
AAER 3759

Violations Alleged

Exchange Act
Sec 13(b)(2)(A)
Sec 13(b)(2)(B)


First Resolution Date 23-Mar-2016
Headline Total Penalty and Disgorgement

See Related Documents

Related Documents:

34-77431 23-Mar-2016 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
On March 23, 2016, the SEC instituted settled cease-and-desist proceedings against Novartis AG. According to the SEC: "These proceedings arise out of violations of the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act of 1977 (the 'FCPA') by respondent Novartis AG ('Novartis') concerning its pharmaceutical operations in China. From at least 2009 to 2013, certain employees and agents of Novartis subsidiaries conducting business in China engaged in transactions and provided things of value to foreign officials, principally healthcare professionals ('HCPs'). These payments took varied forms and were intended to influence the HCPs and thereby increase sales of Novartis pharmaceutical products. Employees and managers in the involved subsidiaries attempted to conceal the true nature of the transactions through the use of complicit third parties and by improperly recording the relevant transactions on the books and records of the respective subsidiaries, which were consolidated in the financial reports of Novartis. Examples include improperly recording the payments as legitimate expenses for travel and entertainment, conferences, lecture fees, marketing events, educational seminars, and medical studies. Novartis also failed to devise and maintain an effective system of internal accounting controls or an effective anti-corruption compliance program."